▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #708 by analyst upside · 2026-09-27
MAZE
Maze Therapeutics, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+136.1%
implied upside to consensus target
Current Price $26.05
Consensus Target $61.5
Bull Target $110.0
Bear Target $46.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
11
Hold
0
Sell
0
52-Week Low $21.95
52-Week High $53.65
YTD Return -34.5%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.44
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $20M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $21.95
52-Week High $53.65
Current Price $26.05
Bear Target $46.0
Bull Target $110.0
● Now $26.05 ● Target $61.5
TRADING DATA
Avg Volume 558K
YTD Return -34.5%
Analyst Count 12
Consensus Buy
Upside to Target +136.1%
Last Updated 2026-09-27

ANALYST SUMMARY

Maze Therapeutics, Inc. (MAZE) is currently trading at $26.05 with a Wall Street consensus price target of $61.5, implying potential upside of 136.1% over the next 12 months. 12 analysts currently cover MAZE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $110.0, while the most cautious has a target of $46.0.

MAZE operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 34.5% year-to-date and is currently trading near the lower end of its 52-week range of $21.95 – $53.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MAZE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-24 31% win rate (48 calls)
Citigroup ● Initiated
Buy 2026-09-23 Building track record
Wedbush reit
Outperform → Outperform 2026-09-23 Building track record
BTIG reit
Buy → Buy 2026-09-22 38% win rate (8 calls)
BTIG reit
Buy → Buy 2026-08-12 38% win rate (8 calls)
Truist Securities - Reiterated
Buy → Buy 2026-04-14 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-03-31 43% win rate (7 calls)
BTIG reit
Buy → Buy 2026-03-25 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →